Regentis Biomaterials Ltd. (RGNT) — IPO Analysis
By Kian O Connor | Updated 4/29/2026
Company Overview
Performance Overview
Since going public at $8.00 per share on Dec 4, 2025, Regentis Biomaterials Ltd. shares have declined 62.5%, disappointing investors who participated in the IPO. The stock currently trades at $3.00, giving the company a market capitalization of $15.5M.
Lockup Expiration
The lockup period for Regentis Biomaterials Ltd. insiders is set to expire on Jun 2, 2026, which is 34 days from now. When the lockup expires, insiders and early investors who received shares before the IPO will be free to sell their holdings on the open market. This can create significant selling pressure and is closely watched by traders and institutional investors alike.
Industry Context
Regentis Biomaterials Ltd. operates in the Medical Instruments & Supplies sector, which has seen varied IPO activity in recent years. The company is headquartered in the United States and is classified under SIC code . Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing RGNT as an investment.
Trading History
Regentis Biomaterials Ltd. is actively trading in the public markets with a current share price of $3.00. The company went public at $8.00 per share, representing a decline of 62.5% from the initial offering price. With a current market capitalization of $15.5M, Regentis Biomaterials Ltd. continues to establish its presence as a publicly traded entity in the Medical Instruments & Supplies.
Important Disclaimer
This analysis of Regentis Biomaterials Ltd. (RGNT) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.